Poland· PL-100492869
Rystiggo
A rozanolixizumab product containing rozanolixizumabum, registered in Poland by UCB Pharma S.A.. The same ATC class is registered in 4 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rozanolixizumab is registered in 4 of 19 countries.
Countries holding a registration under ATC L04AG16 (rozanolixizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Rozanolixizumab · ATC L04AG16
4 / 19 countries
- Belgiumprice
- Ireland
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Rozanolixizumabum
- Manufacturer
- UCB Pharma S.A.
- Country
- Poland (PL)
- ATC code
- L04AG16
- ATC class
- Rozanolixizumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05413787222551
- gtin05413787222780
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rozanolixizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRystiggo 140 mg/mlUCB Pharma
- CzechiaRYSTIGGOUCB Pharma SA, Brusel
- SwitzerlandRystiggo 280 mg/2 ml, solution injectableUCB-Pharma SA
- SpainRYSTIGGO 140 MG/ML SOLUCION INYECTABLEUcb Pharma
- IcelandRystiggoUCB Pharma S.A.*
- SwedenRystiggo 140 mg/ml Injektionsvätska, lösningUCB Pharma S.A.
- United StatesRYSTIGGOUCB, Inc.
- United KingdomRystiggo 280mg/2ml solution for injection vialsUCB Pharma Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rystiggo
- Liechtenstein · Rystiggo
- Norway · Rystiggo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b8a7a2bc-31fd-41a6-81b8-0f43e0fd9e0b GET /v1/drugs/b8a7a2bc-31fd-41a6-81b8-0f43e0fd9e0b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "140 mg/ml",
"packaging": "05413787222551 ¦ Rpz ¦ EU/1/23/1780/001 ¦ 153073\n1 fiol. 2 ml\nRpz ¦ EU/1/23/1780/003 ¦ 158908\n1 fiol. 4 ml\nRpz ¦ EU/1/23/1780/004 ¦ 158909\n1 fiol. 6 ml\n05413787222780 ¦ Rpz ¦ EU/1/23/1780/002 ¦ 158910\n1 fiol. 3 ml",
"substance": "Rozanolixizumabum 140 mg/ml",
"common_name": "Rozanolixizumabum",
"pl_product_id": "100492869",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about rozanolixizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.